期刊
ANALYTICAL CHEMISTRY
卷 93, 期 21, 页码 7562-7570出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.analchem.0c04903
关键词
-
资金
- National Science Foundation [CHE1903967]
- NSF IUCRC Center for Bioanalytical Metrology [1916601]
- Div Of Industrial Innovation & Partnersh
- Directorate For Engineering [1916601] Funding Source: National Science Foundation
Effective monoclonal antibody (mAb) therapies require a specific serum concentration of mAbs to be effective and avoid side effects. This study used microporous nylon membranes functionalized with antibody-binding peptides to capture mAbs from diluted patient sera, allowing for quantitation using native fluorescence. Future work aims to develop rapid point-of-care devices and decrease detection limits for more successful treatments.
Effective monoclonal antibody (mAb) therapies require a threshold mAb concentration in patient serum. Moreover, the serum concentration of the mAb Bevacizumab should reside in a specific range to avoid side effects. Methods for conveniently determining the levels of mAbs in patient sera could allow for personalized dosage schedules that lead to more successful treatments. This work utilizes microporous nylon membranes functionalized with antibody-binding peptides to capture Bevacizumab, Rituximab, or Panitumumab from diluted (25%) serum. Modification of the capture-peptide terminus is often crucial to creating the affinity necessary for effective binding. The high purity of eluted mAbs allows for their quantitation using native fluorescence, and membranes are effective in spin devices that can be used in any laboratory. The technique is effective over the therapeutic range of Bevacizumab concentrations. Future work aims at further modifications to develop rapid point-of-care devices and decrease detection limits.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据